Illumina TruSight Tumor 170
Nov 07, 2016
Illumina has launched TruSight Tumor 170, a next-generation sequencing-based panel that targets SNVs, gene amplifications, gene fusions, and splice variants found in 170 cancer-related genes. The panel analyzes both DNA and RNA and requires 40 nanograms of input from formalin-fixed paraffin-embedded samples. The panel will begin shipping in the first quarter 2017 for research use only.